Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation

Vertex Pharmaceuticals Incorporated167 enrolled

Overview

The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 12 years and older who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.

This was a phase 3 study in subjects with cystic fibrosis (CF) age 12 years and older who have a G551D-CFTR mutation and percent predicted forced expiratory volumn in 1 second (FEV1) between 40% and 90%. Based on in vitro studies and pharmacologic, pharmacokinetic (PK), and safety profiles, ivacaftor was selected for clinical development as a possible treatment for patients with CF. Patients with the G551D mutation were the targeted population for this study because ivacaftor is a potentiator of the gating function of the CFTR protein, and the most prevalent mutation with a gating defect in CF is the G551D mutation. This study was designed to further evaluate the efficacy of ivacaftor in subjects with CF who have a G551D-CFTR gene mutation and to evaluate safety in this population over a longer period than previously studied.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

167

Conditions

Cystic Fibrosis

Interventions

IvacaftorDRUG

150-mg tablets given orally q12h for up to 48 weeks

PlaceboDRUG

Tablet given orally q12h for up to 48 weeks

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed diagnosis of cystic fibrosis (CF) and G551D mutation in at least 1 allele * Forced expiratory volume in 1 second (FEV1) of 40% to 90% (inclusive) of predicted normal for age, gender, and height at Screening. * No clinically significant abnormalities that would have interfered with the study assessments, as judged by the investigator * Willing to use highly effective birth control methods during the study Exclusion Criteria: * History of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject * Acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks of Day 1 of the study * History of alcohol, medication or illicit drug abuse within one year prior to Day 1 * Abnormal liver function ≥ 3x the upper limit of normal * Abnormal renal function at Screening * History of solid organ or hematological transplantation * Pregnant, planning a pregnancy, breast-feeding, or unwilling to follow contraception requirements * Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days prior to Screening * Use of inhaled hypertonic saline treatment * Concomitant use of any inhibitors or inducers of cytochrome P450 3A4 (CYP 3A4)

Locations (65)

Outcomes

Primary Outcomes

Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24

Spirometry (as measured by FEV1) is a standardized assessment to evaluate lung function that is the most widely used endpoint in cystic fibrosis studies.

Time frame: baseline through 24 weeks

Secondary Outcomes

Absolute Mean Change From Baseline in Percent Predicted FEV1 Through Week 48

Spirometry (as measured by FEV1) is a standardized assessment to evaluate lung function that is the most widely used endpoint in cystic fibrosis studies.

Time frame: baseline through 48 weeks

Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Score Through Week 24 and Week 48 (Respiratory Domain Score, Pooled)

The CFQ-R is a health-related quality of life measure for subjects with cystic fibrosis. Each domain is scored from 0 (worst) to 100 (best). A difference of at least 4 points in the respiratory domain score of the CFQ-R is considered a minimal clinically important difference (MCID).

Time frame: baseline through 24 weeks and 48 weeks

Absolute Change From Baseline in Sweat Chloride Concentration Through Week 24 and Week 48

The sweat chloride (quantitative pilocarpine iontophoresis) test is a standard diagnostic tool for cystic fibrosis (CF), serving as an indicator of cystic fibrosis transmembrane conductance regulator (CFTR) activity.

Time frame: baseline through 24 weeks and 48 weeks

Time-to-first Pulmonary Exacerbation Through Week 24 and Week 48

Pulmonary exacerbation was defined as a change in antibiotic therapy (intravenous, inhaled, or oral) for any 4 or more of signs/symptoms such as change in sputum; new or increased hemoptysis; increased cough or dyspnea; malaise, fatigue, or lethargy; temperature above 38 degrees C; anorexia or weight loss; sinus pain/tenderness and discharge; change in physical examination of the chest; decreased pulmonary function by 10%; and radiographic changes indicative of pulmonary infection.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

University of Alabama

Birmingham, Alabama, United States

Kaiser Permanente Medical Care Program

Oakland, California, United States

Cystic Fibrosis Research Office, Stanford University

Palo Alto, California, United States

Rady Children's Hospital

San Diego, California, United States

National Jewish Medical and Research Center

Denver, Colorado, United States

Emory Cystic Fibrosis Center

Atlanta, Georgia, United States

St. Luke's CF Clinic

Boise, Idaho, United States

Children's Memorial Hospital

Chicago, Illinois, United States

Indiana University

Indianapolis, Indiana, United States

University of Iowa

Iowa City, Iowa, United States

...and 55 more locations